AR-A014418

TargetMol
Product Code: TAR-T1881
Supplier: TargetMol
CodeSizePrice
TAR-T1881-5mg5mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1881-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1881-10mg10mg£113.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1881-25mg25mg£144.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1881-50mg50mg£204.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1881-100mg100mg£302.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1881-200mg200mg£371.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor.
CAS:
487021-52-3
Formula:
C12H12N4O4S
Molecular Weight:
308.31
Pathway:
PI3K/Akt/mTOR signaling; Stem Cells
Purity:
0.9994
SMILES:
COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1
Target:
GSK-3

References

1. Bhat R, et al. J Biol Chem. 2003, 278(46), 45937-45945. 2. Carter YM, et al. Cancer Biol Ther. 2014, 15(5). 3. Koh SH, et al. Exp Neurol. 2007, 205(2), 336-346. 4. Martins DF, et al. J Pain. 2011, 12(3), 315-322. 5. Mai C L, Wei X, Gui W S, et al. Differential regulation of GSK-3? in spinal dorsal horn and in hippocampus mediated by interleukin-1beta contributes to pain hypersensitivity and memory deficits following peripheral nerve injury[J]. Molecular pain. 2019, 15: 1744806919826789. 6. Tian J, Li X, Zhao L, et al. Glycyrrhizic Acid Promotes Neural Repair by Directly Driving Functional Remyelination[J]. Food & Function. 2019. 7. Zhang Y, Zhang J, Wang E, et al. Microcystin-Leucine-Arginine Induces Tau Pathology Through B? Degradation via Protein Phosphatase 2A Demethylation and Associated Glycogen Synthase Kinase-3? Phosphorylation. Toxicological Sciences. 2018, 162(2): 475-487. 8. Zhang Y, Zhang J, Wang E, et al. Microcystin-LR induces tau pathology through B? degradation via PP2A demethylation and associated GSK-3? phosphorylation[J]. Toxicological Sciences. 2018 Apr 1;162(2):475-487.